Recombinant HCV type 1b Nonstructural Protein 5 (a.a. 2212-2313)

Name: Recombinant HCV type 1b Nonstructural Protein 5 (a.a. 2212-2313)
SKU: DAG2351
Rating: 5 (1 reviews)

HCV type 1b Nonstructural Protein 5 (aa 2212 - 2313), recombinant protein from E. coli

COA

SDS

Datasheet

Summary

Product Overview

The E.coli derived recombinant protein contains the HCV NS5 Genotype1b immunodominant regions, amino acids 2212-2313.

Nature

Recombinant

Tag/Conjugate

Unconjugated

Purity

> 95%, based on SDS PAGE

Format

Each vial contains 100 μg of lyophilized protein in 1.5M urea, 25 mM Tris-HCl, pH-8, 0.2% Triton-X 50% Glycerol.

Preservative

None

Storage

2-8°C short term, -20°C long term

Introduction

Hepatitis C Virus is a positive, single stranded RNA virus in the Flaviviridae family. The genome is approximately 10, 000 nucleotides and encodes a single polyprotein of about 3, 000 amino acids. The polyprotein is processed by host cell and viral proteases into three major structural proteins and several non structural proteins necessary for viral replication. Several different genotypes of HCV with slightly different genomic sequences have since been identified that correlate with differences in response to treatment with interferon alpha.

Antigen Description

NS5 (non structural protein 5) may play a role in the viral RNA replication of the Hepatitis C Virus. NS5A is a ~56 kDa pleiotropic protein with key roles in both viral RNA replication and modulation of the physiology of the host cell. It"s exact role is not currently known (2008). NS5B (non-structural protein 5B) is an RNA-dependant RNA polymerase responsible for replication of the hepatitis C viral genome, and is currently a principal target for chemotherapeutic inhibition of HCV replication

Keywords

HCV NS5; Hepatitis C virus non structural protein 5; Hepatitis C virus nonstructural protein 5; Hepatitis C Virus NS5; HCV NS5 Genotype 2a; Hepatitis C Virus NS5 Genotype 2a

Citations

Have you cited DAG2351 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response

JOURNAL OF MEDICAL VIROLOGY

Authors: Hanuka, N; Sikuler, E; Tovbin, D; Neville, L; Nussbaum, O; Mostoslavsky, M; Orgel, M; Yaari, A; Manor, S; Dagan, S; Hilzenrat, N; Shemer-Avni, Y

Abstract

Cryptic hepatitis C virus (HCV) infection relates to patients infected chronically with HCV that are seronegative but have HCV-RNA. These patients are not identified by the standard serological tests for HCV, which are based on detection of antibodies to core, NS3 and NS5 antigens. They will, therefore, be wrongly diagnosed as noninfected, and are considered as a potential risk for others. Cryptic HCV infection in dialysis units occurs frequently and, due to medical procedures, is a major factor for contracting the virus when unrecognised. This study was conducted in order to assess the humoral immune responses to E2-antigen in sera of patients infected chronically with HCV. Recombinant E2 protein in enzyme linked immunosorbent assay (ELISA) and Western blot (WB) were used to test the occurrence of anti-E2 antibodies in the sera of patients from the liver clinic and of dialysis patients. The presence of E2 antibodies was found to be correlated with the presence of HCV-RNA and with viral load. Antibodies to the E2 protein could be detected in as many as 30% of the sera from dialysis patients with cryptic HCV infection (HCV-RNA only). The results suggest that detection of anti-E2 antibodies may enhance significantly HCV serological standard testing; especially among patients on dialysis, and that antibodies to envelope E2 protein appear to depend on and correlate with the presence of HCV particles. (C) 2004 Wiley-Liss, Inc.

Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort

VIRUSES-BASEL

Authors: Brandao, Ruben; Marcelino, Rute; Goncalves, Fatima; Diogo, Isabel; Carvalho, Ana; Cabanas, Joaquim; Costa, Ines; Brogueira, Pedro; Ventura, Fernando; Miranda, Ana; Mansinho, Kamal; Gomes, Perpetua

Abstract

This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).